Bradley Pharmaceuticals, Inc. has reported that A Aarons Inc., a subsidiary of Bradley Pharmaceuticals, has announced the launch of methscopolamine bromide tablets, an authorized generic of the company's Pamine tablets.

The company is currently accepting orders. The generic product is available in both 2.5 mg and 5 mg forms, and will meet the same level of quality and be manufactured with the same level of active and inactive pharmaceutical ingredients as Pamine branded products.

Pamine, currently marketed by Bradley through its Kenwood Therapeutics Division, is indicated as adjunctive therapy for peptic ulcer.

Bradley Pharmaceuticals chairman, president and CEO, Daniel Glassman stated, "While Pamine represented approximately 7 per cent of Bradley net sales, during the nine months ended September 30, 2006, and we proactively planned for this introduction and are pleased to be in a position to successfully execute our strategy of extending the life cycles of our established brands.

The introduction of the Pamine generic expands the A. Aarons line of generic products offered to the wholesale and chain pharmacy distribution channels. The A Aarons subsidiary was launched in January of 2006 and its presence in the generic market is beginning to grow both in volume and acceptance. Consistent with other products that have experienced generic competition in our portfolio, we will continue to manufacture and distribute branded Pamine."

Pamine tablets, like other anticholinergics, may produce drowsiness or blurred vision. Patients should be cautioned regarding activities requiring mental alertness, such as driving a motor vehicle or operating machinery. Diarrhoea a may be an early symptom of incomplete intestinal obstruction; in such cases, Pamine is not appropriate treatment and may be harmful. Use of Pamine is contraindicated in patients with glaucoma, blockage in the urinary tract, blockage in the gastrointestinal tract, decreased gastrointestinal motility, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis, paralytic ileus, toxic megacolon complicating ulcerative colitis, and myasthenia gravis.